Prothena Corp (PRTA)

• Market cap: $283M
• 1 day: 0.20%
• 5 days: -7.47%
• 1 month: -33.07%
• 3 months: -63.89%
• 6 months: -60.28%
• Year to date: -62.84%
• 1 year: -76.23%
• 5 years: -46.86%
• 10 years: -89.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Employees: 163

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

180% more call options, than puts

Call options by funds: $3.5M | Put options by funds: $1.25M

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]

2.39% less ownership

Funds ownership: 99.46% [Q4 2024] → 97.07% (-2.39%) [Q1 2025]

6% less funds holding

Funds holding: 169 [Q4 2024] → 159 (-10) [Q1 2025]

13% less capital invested

Capital invested by funds: $741M [Q4 2024] → $647M (-$94.8M) [Q1 2025]

28% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 58

32% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 25

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 21% downside
• Avg. target: $29 475% upside
• High target: $81 1,494% upside

5 analyst ratings

• positive: 4 80%
• neutral: 0 0%
• negative: 1 20%

B of A Securities Tazeen Ahmad	21% downside $4	Underperform Downgraded	28 May 2025
Piper Sandler Yasmeen Rahimi	1,494% upside $81	Overweight Maintained	27 May 2025
JMP Securities Jason Butler	471% upside $29	Market Outperform Maintained	27 May 2025
Chardan Capital Rudy Li	254% upside $18	Buy Maintained	27 May 2025
HC Wainwright & Co. Andrew Fein	176% upside $14	Buy Maintained	27 May 2025